First-in-Human Trial of NRTX-1001 GABAergic Interneuron Cell Therapy for Focal Epilepsy - Updated Clinical Trial Results (P8-9.003)

中间神经元 癫痫 加巴能 神经科学 医学 临床试验 生物 病理 抑制性突触后电位
作者
John Hixson,David C. Spencer,Kim J. Burchiel,Harish Babu,Robert Beach,Jerry J. Shih,Sharona Ben‐Haim,Rebecca O’Dwyer,Sepehr Sani,Derek G. Southwell,Matthew William Luedke,David Blum,Gautam Banik,Marina Bershteyn,Alessandro Bulfone,Brianna G Feld,Holly Finefrock,Luis C. Fuentealba,Ji-Hye Jung,Tia J. Kowal
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:104 (7_Supplement_1) 被引量:10
标识
DOI:10.1212/wnl.0000000000210525
摘要

Objective: To present updated findings from a first-in-human, open-label study of NRTX-1001, an allogeneic GABAergic interneuron therapy, for unilateral drug-resistant temporal lobe epilepsy with mesial temporal sclerosis (NCT05135091). Background: NRTX-1001 is an investigational GABAergic interneuron product derived from human pluripotent stem cells. Preclinical studies demonstrated that hippocampal transplantation significantly reduces seizure frequency in a mouse kainic acid model of focal epilepsy (Bershteyn et.al., Cell Stem Cell 30 :1–20, 2023). Between June 2022 and May 2024, ten subjects were enrolled in the ongoing first-in-human study designed to assess the safety and efficacy of NRTX-1001. Design/Methods: Adults participants with drug-resistant unilateral TLE with mesial temporal sclerosis were administered NRTX-1001 via stereotactic surgery into the hippocampal head and body with intraoperative imaging. Immunosuppression was initiated one week prior to the procedure and is scheduled for tapering after one year. The primary endpoint is safety, with secondary endpoints of seizure frequency, neuroimaging, EEG, cognitive function, and visual fields at one-year post-treatment. Results: As of July 2024, five subjects in the low-dose cohort were at least 6 months post-treatment, with two subjects completing 24 and 19 months of follow-up. The low-dose cohort demonstrated an 82% reduction in disabling seizure frequency over the 4–6-month post-treatment period, with 80% achieving a ≥50% responder rate. No treatment-related serious adverse events (SAEs) have been reported. For all treated subjects, three non-treatment-related SAEs were observed. These were not determined to be related to the cells, procedure, or immunosuppression. Preliminary cognitive assessments revealed improvements in select measures of memory function for some subjects. Updated results for all subjects will be presented. Conclusions: NRTX-1001 administration has been well-tolerated in ten patients with drug-resistant TLE, with preliminary data suggesting significant reductions in seizure frequency and potential cognitive improvements. Unlike current surgical treatment options, NRTX-1001 may provide a non-destructive, cell-based therapeutic approach, potentially providing a restorative option for focal epilepsy. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Dr. Hixson has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Hixson has received personal compensation for serving as an employee of Nile Ai. Dr. Hixson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NextSense Inc. Dr. Hixson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seer Medical. Dr. Hixson has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Expert Institute. Dr. Hixson has received personal compensation in the range of $5,000-$9,999 for serving as a Reviewer with Epilepsy Study Consortium. Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuiticals. Dr. Spencer has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroPace Inc. Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Various. The institution of Dr. Spencer has received research support from NIH. Dr. Spencer has received publishing royalties from a publication relating to health care. Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as a Faculty in Teaching Course supported by unrestricted educational grants with Creative Education Concepts. Kim Burchiel has nothing to disclose. Harish Babu has nothing to disclose. The institution of Dr. Beach has received research support from Neurona. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelis. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SK Life. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion. The institution of Dr. Shih has received research support from Neurona. The institution of Dr. Shih has received research support from NCGS, Inc. Dr. Shih has a non-compensated relationship as a Test Writing Committee Member with ABPN that is relevant to AAN interests or activities. Author has nothing to discloseDr. O'Dwyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. O'Dwyer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK Life Sciences. The institution of Sepehr Sani has received research support from NIH. Sepehr Sani has received intellectual property interests from a discovery or technology relating to health care. Sepehr Sani has received publishing royalties from a publication relating to health care. Derek Southwell has nothing to disclose. Dr. Luedke has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bright Health. Dr. Luedke has received personal compensation in the range of $0-$499 for serving as an Expert Witness for Guidepoint. The institution of Dr. Luedke has received research support from US NAVY. The institution of Dr. Luedke has received research support from Neurona. The institution of Dr. Luedke has received research support from Xenon. Dr. Blum has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Blum has stock in Neurona Therapeutics. Gautam Banik has received personal compensation for serving as an employee of Neurona Therapeutics. Marina Bershteyn has received personal compensation for serving as an employee of Neurona therapeutics. Marina Bershteyn has stock in Neurona therapeutics. Marina Bershteyn has received intellectual property interests from a discovery or technology relating to health care. Dr. Bulfone has received personal compensation for serving as an employee of Neurona Therapeutics Inc. Brianna Feld has received personal compensation for serving as an employee of Neurona Therapeutics. Ms. Finefrock has received personal compensation for serving as an employee of Neurona Therapeutics. Luis Fuentealba has nothing to disclose. Ji-Hye Jung has nothing to disclose. Tia Kowal has received personal compensation for serving as an employee of Neurona Tharapeutics. Tia Kowal has received personal compensation in the range of $100,000-$499,999 for serving as a Scientist with Neurona Theraputics. Sonja Kriks has received personal compensation for serving as an employee of Neurona Therapeutics. Sonja Kriks has stock in Neurona Therapeutics. Sonja Kriks has received intellectual property interests from a discovery or technology relating to health care. Rose Larios has received personal compensation for serving as an employee of Neurona Therapeutics. Seonok Lee has received personal compensation for serving as an employee of Neurona Therapeutics. Author has nothing to discloseYves Maury has received personal compensation for serving as an employee of Neurona Therapeutics. Yves Maury has stock in Neurona therapeutics. Catherine Priest has received personal compensation for serving as an employee of Neurona Therapeutics. Catherine Priest has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk. The institution of Catherine Priest has received research support from CIRM. Sergei Shevchuk has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Joshi has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Joshi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Atara Biotherapeutics. Dr. Joshi has stock in Atara Biotherapeutics. Dr. Nicholas has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Nicholas has stock in Neurona Therapeutics. Dr. Nicholas has received intellectual property interests from a discovery or technology relating to health care.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
凉白开发布了新的文献求助10
1秒前
Akim的应助被Lvc采纳,获得10
1秒前
1秒前
hantongxue完成签到,获得积分10
2秒前
秋风的应助被北林采纳,获得10
2秒前
之鱼之乐完成签到,获得积分10
4秒前
4秒前
称心匕发布了新的文献求助10
5秒前
6秒前
苹果发布了新的文献求助10
6秒前
6秒前
Orange的应助被二甲双胍采纳,获得10
6秒前
shunlimaomi发布了新的文献求助30
8秒前
踌躇前半生完成签到,获得积分10
8秒前
9秒前
10秒前
yanhong发布了新的文献求助30
10秒前
Jiangpeng完成签到,获得积分10
11秒前
秋风的应助被Lvc采纳,获得10
11秒前
Hello的应助被初初初啊采纳,获得10
12秒前
Fyq完成签到,获得积分10
12秒前
程程程发布了新的文献求助10
13秒前
脑洞疼的应助被wx采纳,获得30
13秒前
13秒前
清洋完成签到 ,获得积分10
15秒前
脑洞疼的应助被drizzle采纳,获得20
15秒前
周周发布了新的文献求助50
15秒前
凡fan完成签到,获得积分10
16秒前
荔枝学长完成签到,获得积分10
16秒前
隐形曼青的应助被renn采纳,获得10
17秒前
慕安完成签到,获得积分10
17秒前
老大发布了新的文献求助10
18秒前
zwhqqz完成签到,获得积分10
19秒前
爆米花的应助被初景采纳,获得50
19秒前
挚友完成签到,获得积分10
20秒前
20秒前
小黑完成签到 ,获得积分10
20秒前
单薄茹嫣发布了新的文献求助10
20秒前
米九发布了新的文献求助20
21秒前
ZHANG完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184008
求助须知:如何正确求助?哪些是违规求助? 9573151
关于积分的说明 21829656
捐赠科研通 7781040
什么是DOI,文献DOI怎么找? 3434187
关于科研通互助平台的介绍 2558337
邀请新用户注册赠送积分活动 2480658